GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NEOE:LLY) » Definitions » Cyclically Adjusted PS Ratio

Eli Lilly and Co (NEOE:LLY) Cyclically Adjusted PS Ratio : 29.08 (As of Jun. 10, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted PS Ratio?

As of today (2024-06-10), Eli Lilly and Co's current share price is C$32.57. Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was C$1.12. Eli Lilly and Co's Cyclically Adjusted PS Ratio for today is 29.08.

The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

NEOE:LLY' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.48   Med: 4.99   Max: 28.54
Current: 28.54

During the past years, Eli Lilly and Co's highest Cyclically Adjusted PS Ratio was 28.54. The lowest was 2.48. And the median was 4.99.

NEOE:LLY's Cyclically Adjusted PS Ratio is ranked worse than
98.38% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs NEOE:LLY: 28.54

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Eli Lilly and Co's adjusted revenue per share data for the three months ended in Mar. 2024 was C$13.132. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is C$1.12 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted PS Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.92 7.43 11.14 13.57 20.20

Eli Lilly and Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.48 16.73 18.76 20.20 26.12

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PS Ratio falls into.



Eli Lilly and Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Eli Lilly and Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=32.57/1.12
=29.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Eli Lilly and Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=13.132/131.7762*131.7762
=13.132

Current CPI (Mar. 2024) = 131.7762.

Eli Lilly and Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4.966 100.560 6.508
201409 4.997 100.428 6.557
201412 5.519 99.070 7.341
201503 5.493 99.621 7.266
201506 5.777 100.684 7.561
201509 6.177 100.392 8.108
201512 6.922 99.792 9.141
201603 6.053 100.470 7.939
201606 6.574 101.688 8.519
201609 6.415 101.861 8.299
201612 7.222 101.863 9.343
201703 6.626 102.862 8.489
201706 7.325 103.349 9.340
201709 6.579 104.136 8.325
201712 3.992 104.011 5.058
201803 6.115 105.290 7.653
201806 7.115 106.317 8.819
201809 6.740 106.507 8.339
201812 7.417 105.998 9.221
201903 6.919 107.251 8.501
201906 8.101 108.070 9.878
201909 7.895 108.329 9.604
201912 8.794 108.420 10.688
202003 8.973 108.902 10.858
202006 8.182 108.767 9.913
202009 8.333 109.815 9.999
202012 10.423 109.897 12.498
202103 9.375 111.754 11.055
202106 9.047 114.631 10.400
202109 9.422 115.734 10.728
202112 11.061 117.630 12.391
202203 10.908 121.301 11.850
202206 9.201 125.017 9.698
202209 10.245 125.227 10.781
202212 10.961 125.222 11.535
202303 10.543 127.348 10.910
202306 12.234 128.729 12.524
202309 14.284 129.860 14.495
202312 13.884 129.419 14.137
202403 13.132 131.776 13.132

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (NEOE:LLY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Eli Lilly and Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (NEOE:LLY) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Co (NEOE:LLY) Headlines